Navigation Links
Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
Date:9/11/2008

SEATTLE, Sept. 11 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that the Opposition Division (OD) of the European Patent Office (EPO) has revoked Genentech and Biogen Idec's European Patent 1176981, in its entirety. This patent was generally directed to the use of an anti-CD20 antibody for the treatment of rheumatoid arthritis (RA). The revocation was the result of an opposition proceeding brought by Trubion and several other parties.

The OD, presiding in oral proceedings on Thursday, Sept. 11, 2008, ruled that the patent as granted did not meet the requirements for patentability under the European Patent Convention. Genentech and Biogen Idec have the right to appeal the decision.

"We are extremely pleased with the EPO's decision as it supports the continued development of new and innovative therapies that have the potential to improve patient outcomes for autoimmune and inflammatory diseases. Continued innovation will ultimately provide patients with more effective, convenient, and safer therapies," said Peter Thompson, M.D., FACP, president, chief executive officer and chairman of Trubion.

Forward Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to those related to the expansion of Trubion's product pipeline and its development of new product candidates. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ mate
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
2. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
3. Trubion Announces Presentations at April/May Investor Conferences
4. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
5. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
6. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
7. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
8. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
9. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
10. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
11. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 About POCT ... performed outside a clinical laboratory. It helps in ... appropriate treatments and medication. POCT is gaining popularity ... lifestyle diseases such as diabetes, heart disease, and ... devices are standardized to minimize errors during the ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... an exclusive license for technology developed by the ... expression in plants, including for applications in production of ... The technology was developed under the direction of ... Kultevat and former president of the Danforth Plant Science ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 2
... KBI Biopharma, Inc. (KBI) announced today that it ... with Crucell,s PER.C6(R) human cell line platform, pursuant to ... 6, 2009. Under that agreement, KBI joins the Vendor ... for licensees of the PER.C6(R) cell lines. , ...
... International Products Corporation,s ( http://www.ipcol.com ) ... membrane compatibility and performance studies using a versatile ... any type of membrane media, from UF to RO, and ... "Our goal is to be able to recommend the most ...
... Release Highlights, - Melogliptin continues to demonstrate potential to ... low incidence of, hypoglycemia and neutral effect on ... by end 2009, - IND approved by USFDA, ... Indian company to have a truly global innovative drug for ...
Cached Biology Technology:KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R) 2International Products Corp.'s Lab Offers Filter Membrane Compatibility and Studies 2Glenmark's Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials 2
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... fairness did not evolve for the sake of fairness ... of continued cooperation, so say Frans de Waal, PhD, ... about inequity aversion (IA), which is defined as a ... in Science . , Their conclusion comes ... to address their hypothesis that it is the evolution ...
(Date:9/18/2014)... A new GSA Bulletin study uses ... Rio Puerco and Chaco Wash in northern New Mexico, ... salt cedar and willow, investigators were able to precisely ... They then combined this data with aerial imagery, LiDAR, ... of these arroyos. , Arroyos are deep, oversized channels ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... as to how HIV evades the human immune system ... The findings suggest some HIV vaccines may have failed ... patient's own immune system is programmed to destroy. , ... which recognize and latch onto the HIV protein gp41, ...
... Africa, where days of heavy rains and flooding have led ... are reporting an unprecedented rise in Somalia's Shabelle River and ... centre of the country, the United Nations said today. , ... Affairs (OCHA), reports yesterday from Belet Weyne, close to the ...
... to recover in adolescent females once they stop using ... a study funded by the National Institute of Child ... Health. , Previous studies had shown that women who ... a loss of bone mineral density during the time ...
Cached Biology News:New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines 2New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines 3Bone Density Recovers After Teens Stop Injected Contraceptive 2Bone Density Recovers After Teens Stop Injected Contraceptive 3
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
... for calibrating single-channel and multi-channel pipettes. ,Thanks ... carrying case, the MCP1-S is ideal for ... on-site at the users premises. The unit ... individual channels are tested automatically. Multi-channel pipettes ...
... ChIP-on-chip Microarray is specifically designed for ... DNA binding proteins by pairing chromatin ... This set delivers robust hybridization and ... binding events and fewer false positives. ...
... Genome ChIP-on-chip Microarray is specifically designed ... cerevisiae) DNA binding proteins by pairing ... microarrays. This set delivers robust hybridization ... true binding events and fewer false ...
Biology Products: